In the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial, higher tBil was associated with an increased risk of mortality, while ALT and AST were not.8 This evidence concerns the gene GPT and hydrops fetalis.